Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder
New data demonstrates a therapeutic effect for at least 10 days after a single subcutaneously (SC) injection of an extended-release…
Pharmaceuticals, Biotechnology and Life Sciences
New data demonstrates a therapeutic effect for at least 10 days after a single subcutaneously (SC) injection of an extended-release…
MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) — TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on…
BAUDETTE, Minn., Sept. 18, 2023 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that…
DURHAM, N.C., Sept. 18, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable,…
VANCOUVER, British Columbia, Sept. 15, 2023 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA)…
The Company Has Received the Last Portion of the Final Earnout Milestone Payment, With a Value of Approximately $1.5 Million…
WATERTOWN, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (“Neumora”), a clinical-stage biopharmaceutical company redefining neuroscience drug development,…
VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) — Digicann Ventures Ltd. (“Digicann” or the “Company”) (CSE: DCNN) (OTCPK: AGFAD),…
Priority Review Continues with Successful Facility Inspections Completed,no Major Review Issues FDA Extends PDUFA Date to February 24, 2024 on…
NEWARK, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing…